Provided by Tiger Trade Technology Pte. Ltd.

Innoviva

21.21
+0.34001.63%
Post-market: 21.210.00000.00%19:30 EDT
Volume:507.57K
Turnover:10.73M
Market Cap:1.53B
PE:4.93
High:21.28
Open:20.80
Low:20.78
Close:20.87
52wk High:25.15
52wk Low:16.52
Shares:72.25M
Float Shares:69.02M
Volume Ratio:0.69
T/O Rate:0.74%
Dividend:- -
Dividend Rate:- -
EPS(TTM):4.30
EPS(LYR):3.30
ROE:36.68%
ROA:6.95%
PB:1.24
PE(LYR):6.43

Loading ...

Armata Pharmaceuticals Wins New U.S. Patents for AP-SA02, AP-PA02 Phage Programs

Reuters
·
Oct 07

Oppenheimer Upgrades Innoviva to Outperform From Neutral, $35 Price Target

MT Newswires Live
·
Sep 23

Innoviva Coverage Assumed by Oppenheimer at Outperform

Dow Jones
·
Sep 23

Armata Says AP-SA02 Genetic Diversity May Boost Killing of Some Staph Aureus Isolates in Clinical Testing

Reuters
·
Sep 21

Armata Says FDA Grants Breakthrough Therapy Designation for AP-SA02 in Complicated Staph Aureus Bacteremia

Reuters
·
Sep 14

Armata Pharmaceuticals CEO Deborah Birx Presents at H.C. Wainwright Global Investment Conference

Reuters
·
Sep 10

Armata Says Inhaled Phage Candidate AP-PA02 Completes Phase 2 Trials in Cystic Fibrosis, Bronchiectasis Patients

Reuters
·
Sep 03

Innoviva Management Participates in Cantor Global Healthcare Conference Fireside Chat

Reuters
·
Sep 02

Innoviva (INVA) Faces A Valuation Test, Is The Discount Too Wide?

Simply Wall St.
·
Aug 26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Innoviva (INVA) and Pfizer (PFE)

TIPRANKS
·
Aug 21

Basilea Publishes Investor Presentation on Anti-Infectives Strategy and Pipeline Progress

Reuters
·
Aug 18

Innoviva management to meet virtually with Cantor Fitzgerald

TIPRANKS
·
Aug 17

Armata Swings to FY26 Q2 Net Income of $74.14 Million; Operating Loss Widens to $10.31 Million

Reuters
·
Aug 13

Does Innoviva’s Q2 Loss and Buyback-Fueled EPS Shift Change The Bull Case For INVA?

Simply Wall St.
·
Aug 08

Innoviva, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 06

Innoviva Q2 EPS $(1.14) Misses $0.40 Estimate, Sales $119.600M Beat $110.985M Estimate

Benzinga Earnings
·
Aug 06

Innoviva Q2 FY26 Swings to Net Loss of $83.4 Million; Revenue Rises 19% to $119.6 Million

Reuters
·
Aug 06

Innoviva Q2 Royalty Revenue USD 56.334 Million

Reuters
·
Aug 06

Basilea Publishes Investor Presentation on Anti-Infectives Strategy, Pipeline and Hospital Brands Cresemba, Zevtera

Reuters
·
Aug 05

Basilea Publishes Investor Presentation on Hospital Anti-infectives Portfolio and Pipeline

Reuters
·
Jul 29